prikaz prve stranice dokumenta The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
  Download
PDF 2.72 MB
Scientific paper - Original scientific paper
The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
Biomedicines, 11 (2023), 4; 1025. https://doi.org/10.3390/biomedicines11041025
Osmanović Barilar, Jelena; Babić Perhoč, Ana; Knezović, Ana; Homolak, Jan; Virag, Davor; Šalković-Petrišić, Melita

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Osmanović Barilar, J., Babić Perhoč, A., Knezović, A., Homolak, J., Virag, D. & Šalković Petrišić, M. (2023). The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease. Biomedicines, 11. (4). doi: 10.3390/biomedicines11041025

Osmanović Barilar, Jelena, et al. "The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease." Biomedicines, vol. 11, no. 4, 2023. https://doi.org/10.3390/biomedicines11041025

Osmanović Barilar, Jelena, Ana Babić Perhoč, Ana Knezović, Jan Homolak, Davor Virag and Melita Šalković Petrišić. "The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease." Biomedicines 11, no. 4 (2023). https://doi.org/10.3390/biomedicines11041025

Osmanović Barilar, J., et al. (2023) 'The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease', Biomedicines, 11(4). doi: 10.3390/biomedicines11041025

Osmanović Barilar J, Babić Perhoč A, Knezović A, Homolak J, Virag D, Šalković Petrišić M. The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease. Biomedicines [Internet]. 2023 March 27 [cited 2024 December 29];11(4). doi: 10.3390/biomedicines11041025

J. Osmanović Barilar, A. Babić Perhoč, A. Knezović, J. Homolak, D. Virag and M. Šalković Petrišić, "The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease", Biomedicines, vol. 11, no. 4, March 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:695960. [Accessed: 29 December 2024]

Metadata
Title (english)The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
AuthorJelena Osmanović Barilar
AuthorAna Babić Perhoč
AuthorAna Knezović
AuthorJan Homolak
AuthorDavor Virag
AuthorMelita Šalković-Petrišić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Abstract (english)
Type 2 diabetes mellitus increases the risk of sporadic Alzheimer’s disease (sAD), and antidiabetic drugs, including the sodium–glucose cotransporter inhibitors (SGLTI), are being studied as possible sAD therapy. We have explored whether the SGLTI phloridzin may influence metabolic and cognitive parameters in a rat model of sAD. Adult male Wistar rats were randomized to a control (CTR), an sAD-model group induced by intracerebroventricular streptozotocin (STZ-icv; 3 mg/kg), a CTR+SGLTI, or an STZ-icv+SGLTI group. Two-month-long oral (gavage) SGLTI treatment (10 mg/kg) was initiated 1 month after STZ-icv and cognitive performance tested prior to sacrifice. SGLTI treatment significantly decreased plasma glucose levels only in the CTR group and failed to correct STZ-icv-induced cognitive deficit. In both the CTR and STZ-icv groups, SGLTI treatment diminished weight gain, decreased amyloid beta (Aβ) 1-42 in duodenum, and decreased the plasma levels of total glucagon-like peptide 1 (GLP-1), while the levels of active GLP-1, as well as both total and active glucose-dependent insulinotropic polypeptide, remained unchanged, compared to their respective controls. The increment in GLP-1 levels in the cerebrospinal fluid and its effect on Aβ 1-42 in duodenum could be one of the molecular mechanisms by which SGLTIs indirectly induce pleiotropic beneficial effects.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 11, no. 4, 1025
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines11041025
URN:NBNurn:nbn:hr:105:695960
Publication2023-03-27
ProjectNumber: IP-2018-01-8938
Title (croatian): Mehanizmi nutrijentom posredovanih učinaka endogenog glukagonu sličnog peptida-1 na kognitivne i metaboličke poremećaje u eksperimentalnim modelima neurodegenerativnih bolesti
Acronym: NutrientGLP-1
Leader: Melita Šalković-Petrišić
Jurisdiction: Croatia
Funding stream: IP
ProjectNumber: KK.01.1.1.01.0007
Title (english): Eksperimentalna i klinička istraživanja hipoksijsko-ishemijskog oštećenja mozga u perinatalnoj i odrasloj dobi
Leader: Ivica Kostović
Jurisdiction: eu
Document URLhttps://www.mdpi.com/2227-9059/11/4/1025
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-10-27 08:12:32